摘要
研发投入被认为是提升企业竞争力的重要因素。基于2012—2021年92家医药制造业上市企业数据,构建企业绩效评价指标体系,运用主成分分析法测算企业绩效综合得分,并通过回归分析研究研发投入强度对企业绩效的影响。结果表明:医药制造业上市企业研发投入强度与当期企业绩效存在显著的负相关;但滞后3年与滞后4年的企业研发投入对企业绩效提升有显著积极作用。研究结果可为医药制造业企业改善研发投入结构、政府进一步调整或制定研发和创新政策提供支撑。
R&D investment is considered to be an important factor to enhance the competitiveness of enterprises.Based on the data of 92 listed companies in pharmaceutical manufacturing industry from 2012 to 2021,the evaluation index system of enterprise performance was established.Then using the principal component analysis,the comprehensive enterprise performance score was calculated.And the regression analysis was used for studying the impact of R&D intensity on enterprise performance.The results show a significant negative correlation between R&D intensity and the current enterprise performance.But R&D intensity lagging behind three years or four years has a significant positive effect on improving enterprise performance.The results can provide support for pharmaceutical manufacturing enterprises to optimize structure of the R&D investment and help the government to adjust or formulate policies on R&D and innovation.
作者
林君妮
许艺苹
陈舒
LIN Junni;XU Yiping;CHEN Shu(Science and Technology Development Research Center of Fujian,Fuzhou 350001,China)
出处
《科技和产业》
2023年第5期56-62,共7页
Science Technology and Industry
基金
福建省创新战略研究项目(2021R0103)。
关键词
研发投入强度
企业绩效
主成分分析
回归分析
R&D intensity
enterprise performance
principle component analysis
regression analysis
